(NASDAQ: HLVX) Hillevax's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.21%.
Hillevax's revenue in 2023 is N/A.On average, 1 Wall Street analysts forecast HLVX's revenue for 2026 to be $416,815,750, with the lowest HLVX revenue forecast at $416,815,750, and the highest HLVX revenue forecast at $416,815,750. On average, 2 Wall Street analysts forecast HLVX's revenue for 2027 to be $3,876,053,022, with the lowest HLVX revenue forecast at $1,467,191,440, and the highest HLVX revenue forecast at $6,284,914,605.
In 2028, HLVX is forecast to generate $17,619,635,384 in revenue, with the lowest revenue forecast at $17,619,635,384 and the highest revenue forecast at $17,619,635,384.